Ligand to Participate in March Investor Conferences
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in two major healthcare investor conferences this March 2025. CEO Todd Davis and CFO Tavo Espinoza will represent the company at both events in Miami.
The management team will attend the Leerink Partners Global Healthcare Conference on March 10, engaging in one-on-one meetings with investors. Following this, they will participate in the Barclays 27th Annual Global Healthcare Conference on March 12, where they will join a fireside chat at 12:00 p.m. ET and conduct additional one-on-one meetings.
Investors interested in scheduling individual meetings with Ligand's management should reach out to their Leerink or Barclays representatives to arrange appointments.
Ligand Pharmaceuticals (Nasdaq: LGND) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a marzo 2025. Il CEO Todd Davis e il CFO Tavo Espinoza rappresenteranno l'azienda in entrambi gli eventi a Miami.
Il team di gestione parteciperà alla Global Healthcare Conference di Leerink Partners il 10 marzo, impegnandosi in incontri individuali con gli investitori. Successivamente, parteciperanno alla 27ª Conferenza Annuale Globale sulla Salute di Barclays il 12 marzo, dove parteciperanno a una chiacchierata informale alle 12:00 ET e condurranno ulteriori incontri individuali.
Gli investitori interessati a pianificare incontri individuali con il management di Ligand dovrebbero contattare i loro rappresentanti di Leerink o Barclays per organizzare appuntamenti.
Ligand Pharmaceuticals (Nasdaq: LGND) ha anunciado su participación en dos importantes conferencias de inversores en el sector salud este marzo de 2025. El CEO Todd Davis y el CFO Tavo Espinoza representarán a la compañía en ambos eventos en Miami.
El equipo de gestión asistirá a la Conferencia Global de Salud de Leerink Partners el 10 de marzo, participando en reuniones uno a uno con inversores. Después, participarán en la 27ª Conferencia Anual Global de Salud de Barclays el 12 de marzo, donde se unirán a una charla informal a las 12:00 p.m. ET y llevarán a cabo más reuniones individuales.
Los inversores interesados en programar reuniones individuales con la dirección de Ligand deben comunicarse con sus representantes de Leerink o Barclays para organizar citas.
리간드 제약 (Nasdaq: LGND)는 2025년 3월에 열리는 두 개의 주요 의료 투자자 회의에 참여한다고 발표했습니다. CEO 토드 데이비스와 CFO 타보 에스피노자가 마이애미에서 두 행사에 참석하여 회사를 대표합니다.
경영진은 3월 10일에 열리는 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에 참석하여 투자자와 일대일 미팅을 진행할 예정입니다. 이후 3월 12일에는 바클레이즈 제27회 연례 글로벌 헬스케어 컨퍼런스에 참여하여 오후 12시(동부 표준시)에는 화로 옆 대화에 참석하고 추가적인 일대일 미팅을 진행할 것입니다.
리간드 경영진과 개별 미팅을 예약하고자 하는 투자자들은 리어링크 또는 바클레이즈 대표에게 연락하여 약속을 잡아야 합니다.
Ligand Pharmaceuticals (Nasdaq: LGND) a annoncé sa participation à deux grandes conférences d'investisseurs dans le secteur de la santé en mars 2025. Le PDG Todd Davis et le directeur financier Tavo Espinoza représenteront l'entreprise lors des deux événements à Miami.
L'équipe de direction assistera à la Conférence mondiale sur la santé de Leerink Partners le 10 mars, participant à des réunions individuelles avec des investisseurs. Par la suite, ils participeront à la 27e Conférence annuelle mondiale sur la santé de Barclays le 12 mars, où ils prendront part à une discussion informelle à 12h00 ET et réaliseront d'autres réunions individuelles.
Les investisseurs souhaitant planifier des réunions individuelles avec la direction de Ligand doivent contacter leurs représentants de Leerink ou de Barclays pour organiser des rendez-vous.
Ligand Pharmaceuticals (Nasdaq: LGND) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitssektor im März 2025 bekannt gegeben. CEO Todd Davis und CFO Tavo Espinoza werden das Unternehmen bei beiden Veranstaltungen in Miami vertreten.
Das Management-Team wird an der Global Healthcare Conference von Leerink Partners am 10. März teilnehmen und sich in Einzelgesprächen mit Investoren engagieren. Danach nehmen sie an der 27. jährlichen Global Healthcare Conference von Barclays am 12. März teil, wo sie um 12:00 Uhr ET an einem Fireside-Chat teilnehmen und weitere Einzelgespräche führen werden.
Investoren, die an der Planung individueller Meetings mit dem Management von Ligand interessiert sind, sollten sich an ihre Vertreter von Leerink oder Barclays wenden, um Termine zu vereinbaren.
- None.
- None.
JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:
- Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025.
- Barclays 27th Annual Global Healthcare Conference (Miami). Management will participate in a fireside chat on March 12, 2025 at 12:00 p.m. ET.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Leerink or Barclays representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
Which investor conferences will Ligand Pharmaceuticals (LGND) attend in March 2025?
What type of presentations will LGND make at the March 2025 healthcare conferences?
Who will represent Ligand (LGND) at the March 2025 investor conferences?
How can investors schedule meetings with LGND management at these conferences?
